Dyne Therapeutics grabs $115M to ramp up muscle disease pipeline
Dyne Therapeutics is back at the VC well—this time, it’s raising $115 million to bankroll a pipeline of treatments for muscle diseases including its lead programs for Duchenne muscular dystrophy and two other muscle-wasting diseases.